What Kai Tong Treats: Main Uses and Benefits

The medicine is used across conditions where functional stability becomes affected by circulatory symptoms, relevant when supportive symptom management is appropriate.

It is relevant for easing symptoms in three primary domains: used for managing symptoms of refractory erectile function failure, is relevant for easing severe symptoms of Critical Limb Ischemia, and applied in addressing circulatory symptoms associated with neonatal crises.

This medicine is commonly used to address symptom clusters that interfere with daily functioning or create noticeable physiological strain. For adult patients, it may assist with maintaining functional stability necessary for sexual performance and contributes to easing discomfort associated with advanced peripheral vascular disease. For newborns, it assists with maintaining functional stability of circulation during a critical period.

Quick Fact: Support for Acute Circulatory Symptoms

“The use of this medicine is designed to provide symptomatic relief and support the patient during episodes of heightened discomfort or situations involving heightened physiological stress.”

Regulatory References

1. NIH MedlinePlus overview of Alprostadil

Eligibility Map: Who can and cannot use Kai Tong — official regulatory information

The eligibility for this medicine is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use based on age, coexisting conditions, and anatomical factors.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Males (age ge 18 years) for one indication. Neonates for specific, life-critical congenital heart defects.
Populations for whom use is contraindicated	Men with penile implants or anatomical deformation (e.g., Peyronie's disease). Men with conditions predisposing to priapism (e.g., sickle cell anemia, leukemia). Neonates with Respiratory Distress Syndrome (RDS).
Age-related eligibility rules	Adults are approved for one indication. The medicine is not indicated for general pediatric use. Neonates weighing less than 2 kg require close monitoring due to an increased risk for apnea.
Condition-specific eligibility rules	Pharmacokinetics in patients with hepatic or renal insufficiency have not been formally evaluated. Use requires caution in patients taking anticoagulants.
Pregnancy and lactation eligibility	The medicine is not indicated for use in female patients. Male partners should use a barrier method during intercourse with a pregnant partner.

---

Connection to the overall eligibility profile

Regulatory documents define eligibility through absolute contraindications linked to conditions that increase the risk of severe complications, such as priapism, or anatomical factors that preclude safe administration. Eligibility is also structured by strict age segmentation, formally approving use in adult males for one indication and neonates for another, while formally excluding general use in women and older children. Specific population restrictions are applied where formal study data in groups like those with organ impairment is currently lacking.

Interactions with other medicines and products

Official regulatory information addresses interactions that significantly alter the concentration or effects of [Kai Tong] or co-administered medicinal products. The profile primarily focuses on pharmacokinetic relationships involving metabolic enzymes and drug transporters, alongside critical pharmacodynamic concerns.

Interaction Scope	Statement based on Regulatory Structuring
Interacting Product Categories	Strong CYP3A4 inhibitors and inducers; P-glycoprotein (P-gp) inhibitors and inducers; Agents with known QT interval prolonging effects; pH-altering substances (e.g., antacids).
Mechanistic Basis	CYP3 A4 metabolism and P-gp transport are primary determinants of [Kai Tong]'s systemic exposure. Inhibition of these pathways increases drug levels; induction decreases levels.

Official Interaction Statements:

• Co-administration with potent CYP3 A4 inhibitors (e.g., Ketoconazole) is generally contraindicated due to a significant, documented increase in [Kai Tong] exposure. Conversely, CYP3 A4 inducers (e.g., Rifampicin) are restricted as they lead to decreased systemic drug concentration.
• [Kai Tong] is a substrate for the P-glycoprotein efflux transporter. Concomitant use with strong P-gp inducers can substantially reduce absorption and efficacy, while P-gp inhibitors may increase exposure.
• The use of other agents known to prolong the QT interval should be avoided or closely managed due to an anticipated additive pharmacodynamic effect on cardiac repolarization.
• Administration of pH-altering agents, such as certain antacids, must be temporally separated from [Kai Tong] to avoid physical chelation or altered dissolution that impairs gastrointestinal absorption.

1. Activation of Prostaglandin Receptor Pathways

The drug acts as a direct synthetic agonist, meaning it mimics and activates the body’s natural Prostanoid Receptors, specifically the EP2 and EP4 subtypes, located on smooth muscle cell membranes. This mechanism is independent of neural or psychological stimulation, allowing for the direct activation of the vascular pathway.

2. Cascading Signal for Smooth Muscle Relaxation

Receptor activation triggers the adenylate cyclase enzyme, rapidly increasing the internal cellular signal, cyclic AMP ( cAMP). This surge initiates a molecular cascade where PKA (Protein Kinase A) inhibits the machinery responsible for muscle contraction, resulting in a marked reduction of vascular smooth muscle tone.

3. Localized Hemodynamic Adjustment

The resulting relaxation of the arterial walls causes a local reduction in vascular resistance, leading to vasodilation. This physiological adjustment results in an increased influx of arterial blood, leading to localized blood pooling. The mechanism dictates the localization of the action to the site of administration.

How Kai Tong is Used: Official Administration Guidelines

Kai Tong (Alprostadil) is a specialized medicinal preparation whose use is strictly defined by its parenteral administration routes and indication-specific dosing protocols. The product, supplied as a lyophilized powder, requires reconstitution with a sterile diluent just prior to use.

Official Usage Protocols

Administration Component	Guideline Description
Route of Administration	Primarily Intracavernosal Injection or Continuous Intravenous (IV) Infusion.
Dosing Regimen	Injection: Initial dose titration is mandatory, starting at 1.25 mcg or 2.5 mcg, with a maximum single dose of 60 mcg. IV Infusion: Dosing is often weight-based for neonates (0.05 to 0.1 mcg/kg/minute) or a scheduled 40 mcg twice daily for other systemic uses.
Frequency Constraints	Intracavernosal use is limited to a maximum of three times per week with a mandatory interval of at least 24 hours between doses. Continuous IV Infusions must not be interrupted.
Procedural Condition	Initial self-administration doses must be performed under the supervision of a healthcare provider. The injection site must be alternated for each dose.

These official instructions establish that the drug must be administered in a controlled manner, with the initial parenteral dosing requiring medical oversight. The strict frequency and specialized administration steps ensure the preparation is used only according to the established guidelines for its potent pharmacological profile.

Kai Tong: Recent Clinical Evidence

This section provides a patient-friendly summary of the available research and clinical studies for Kai Tong, describing the types of evidence that exist and the areas that researchers have focused on. This information is intended to contextualize the medicine's use and should not be considered medical advice or a prediction of individual outcomes.

Evidence for Use in Refractory Erectile Function Failure

Research exploring the effects of this medicine for erectile function typically involves controlled trials, including short-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies primarily focused on adult males who did not achieve satisfactory outcomes with oral therapies. Findings describe patterns observed in the studies where functional scores and the ability to achieve a sufficient response for activity were measured. When compared to placebo, the research describes patterns related to functional scores when the medicine was administered locally. Research highlights that results apply only to the specific populations studied, and findings were mixed depending on the patient subgroup. What remains uncertain is the long-term characterization of these outcomes; follow-up durations were limited in many primary clinical evaluation studies.

Evidence for Use in Acute Neonatal Circulatory Support

Research for the use of Kai Tong in newborns with ductal-dependent congenital heart defects is conducted in critical, highly specialized settings. The evidence is largely derived from observational case series and retrospective chart reviews. Studies monitored acute physiological outcomes related to systemic or functional imbalance. Researchers measured critical markers such as blood oxygen saturation ( SpO2) and blood pressure. Case series and observational studies reported how physiological outcomes evolved in the observed neonate populations. The study outcomes focus strictly on short-term stability until a surgical procedure can be performed, and long-term developmental outcomes are outside the scope of this acute stabilization research.

Evidence in Special Populations and Uncertainties

The evidence base highlights areas of remaining uncertainty. Comparative evidence is lacking against several contemporary alternative treatments for adult conditions. Data for certain groups, such as patients with significant kidney or liver impairment, remain insufficient, as these groups were often excluded from primary clinical evaluation studies. Ultimately, findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Alprostadil - StatPearls - NCBI Bookshelf (Review of ED and Neonatal Indications)
2. Alprostadil Urogenital: MedlinePlus Drug Information (Patient-facing regulatory and general evidence summary)
3. Prostanoids for critical limb ischaemia - Cochrane Review (2018 update)

Common questions about Kai Tong (FAQ)

Q: Does Kai Tong cause any known long-term side effects?

A: Regulatory documents state that serious, long-term effects related to the administration area have been noted, such as penile fibrosis, angulation, or Peyronie’s disease, which are anatomical changes. In neonatal patients, some specific effects are described as being associated with prolonged use.

Q: Is it possible for a person to build up a 'tolerance' to Kai Tong over time?

A: Official drug documents do not typically use the specific term 'tolerance' or 'tachyphylaxis.' However, official dosing guidelines emphasize using the lowest effective dose to achieve the desired response. Regulatory documents do not offer definitive statements on a patient developing tolerance to the drug over time.

Q: Does taking Kai Tong require regular monitoring (e.g., blood tests)?

A: Official documents define that periodic physical examinations of the administration site are part of the guidance to check for anatomical changes like penile fibrosis or angulation. Routine blood tests are not commonly cited as a general necessity for monitoring the medicine's primary use.

Q: What is the typical time frame for the 'peak' concentration of Kai Tong in the body?

A: According to the official product information, the maximum concentration of the drug's major metabolite is described as typically occurring approximately 30 minutes after injection. The active drug substance itself has a very short half-life, meaning it is quickly processed by the body, usually within 5 to 10 minutes.

Q: What is the maximum period of time generally mentioned in official documents for taking Kai Tong?

A: Regulatory documents strictly define the frequency limits, such as a maximum of three doses per week. Specific total treatment durations spanning months or years are not defined in official documentation. Long-term safety data that exists is noted as being limited in duration in some clinical evaluation studies.

Q: Is Kai Tong an over-the-counter medicine?

A: No, Kai Tong is strictly classified as a prescription-only medicine. It is intended for targeted, specialized use and requires an order from a qualified healthcare provider. It is not available for purchase without a prescription.

Q: Are there common but minor side effects of Kai Tong that most people experience?

A: The official product information documents the most frequently occurring adverse reactions. These often relate to the site of administration, with pain being noted as a very common effect. Other common reported effects include flushing, hypotension (low blood pressure), and headache.

Q: How quickly can a person generally expect to feel the effects of Kai Tong?

A: The onset of the effect is generally rapid and occurs due to the medicine’s direct administration route. For the primary adult indication, the onset is generally described in official sources as occurring within a range of 5 to 20 minutes.

Q: How long does the effect of one dose of Kai Tong typically last?

A: The intended therapeutic effect of a single dose is described in clinical research as generally lasting approximately 30 to 60 minutes. The goal is to achieve an effect that resolves within one hour. Erections persisting longer than four hours are officially designated as a serious reaction.

Q: Can Kai Tong be taken by people who are sensitive to other similar medicines?

A: Official prescribing information strictly states that Kai Tong is contraindicated for use in any patient who has a known hypersensitivity or allergic reaction to the active ingredient, Alprostadil, or any other components in the product. Information regarding individual allergies or sensitivities is determined by a healthcare provider.

Q: Does the time of day a person takes Kai Tong matter?

A: Official instructions specify strict limits on the dose frequency and the minimum interval between doses, such as a mandatory 24 hours between injections. However, regulatory documents do not specify any restrictions related to the time of day, mealtimes, or circadian rhythm when the medicine is administered.

Q: Is it normal to feel a specific sensation (e.g., slight dizziness) when starting Kai Tong?

A: Dizziness and hypotension (low blood pressure) are specifically listed as common documented adverse effects. This is because the drug's vasodilating action can sometimes lead to these systemic effects.

Q: Where can I find the official regulatory documents for Kai Tong?

A: Official documents like the Prescribing Information and the Summary of Product Characteristics (SmPC) are publicly accessible. They can be found on the websites of government drug agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), often by searching for the active ingredient, Alprostadil.

Q: Has Kai Tong been approved in major regions like the US or Europe?

A: Yes, medicinal products that contain the active ingredient Alprostadil have received marketing authorization and approval for specific, regulated indications in major regions. These regions include the United States, as authorized by the FDA, and countries within the European Union, following assessment by the EMA.

Q: Is it generally acceptable to use alcohol while taking Kai Tong?

A: Regulatory-sourced patient guidance states that the topic of alcohol consumption should be discussed with a healthcare provider. Alcohol can cause vasodilation, which may potentially contribute to or increase the effect of Kai Tong’s action.

How to Store and Dispose of Kai Tong?

Regulatory documents mandate specific conditions for storing and disposing of Kai Tong (Alprostadil).

Storage Requirements

The unopened lyophilized powder must be stored at controlled room temperature, generally 20 C to 25 C (68 F to 77 F), and must be protected from excess heat. It is strictly required that the powder must not be frozen. The product should be kept in its original packaging and stored out of the sight and reach of children.

Stability and Handling

The reconstituted solution is for single use only. It must be used immediately after mixing; if not used right away, it must be discarded if not administered within 24 hours. The reconstituted solution must not be refrigerated or frozen.

Disposal Instructions

All used injection materials, including the syringe, needle, and vial, must be safely and properly discarded. Any unused or expired medication must be disposed of according to local regulatory requirements for sharps and pharmaceutical waste.